The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, such as transplant rejection and autoimmune diseases.
Amide and diamide inhibitors of IMPDH enzyme for use in treating IMPDH-associated disorders
申请人:Bristol-Myers Squibb Company
公开号:US06624184B1
公开(公告)日:2003-09-23
The present invention discloses the identification of the inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, such as transplant rejection and autoimmune diseases.
Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.
[EN] METABOLISM-MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DU MÉTABOLISME ET UTILISATIONS ASSOCIÉES
申请人:UNIV QUEENSLAND
公开号:WO2006017896A1
公开(公告)日:2006-02-23
The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5' monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.